Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03406104 · ClinicalTrials.gov registry record · Phase 3
RESCUE and REVERSE Long-term Follow-up
A Phase 3 study of Leber Hereditary Optic Neuropathy, sponsored by GenSight Biologics.
- Completed
- Registry status
- Phase 3
- Development phase
- 62
- Enrollment target
- 7
- Study locations
NCT03406104 is a Phase 3 study of Leber Hereditary Optic Neuropathy that has completed, run by GenSight Biologics. The registered enrollment target is 62 participants. The trial reports 7 study locations across 5 states.
The verdict
NCT03406104, a Phase 3 study of Leber Hereditary Optic Neuropathy, has completed, sponsored by GenSight Biologics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 62 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this clinical trial is to assess the long-term safety and efficacy of GS010, a gene therapy, and assess the quality of life in subjects with LHON due to the G11778A ND4 mitochondrial mutation and who were treated in the Rescue or Reverse studies.
Conditions Studied
Interventions
- GENETIC GS010
- OTHER Sham Intravitreal Injection
Study Locations (7)
Other
- CHNO Les Quinze Vingts - Paris
- LMU Klinikum der Universität München / Friedrich-Baur-Institut - Munich
- Ospedale Bellaria - Bologna
California
- Doheny Eye Center UCLA - Pasadena
Georgia
- Emory University Hospital - Atlanta
Pennsylvania
- Wills Eye Institute - Philadelphia
Greater London
- Moorfields Eye Hospital - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2018-01-09 |
| Est. Completion | 2022-07-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03406104
The ClinicalTrials.gov registry entry for NCT03406104 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GenSight Biologics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leber Hereditary Optic Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which GS010 is the first listed.
NCT03406104 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT03406104 about?
NCT03406104 is a clinical study titled "RESCUE and REVERSE Long-term Follow-up". The goal of this clinical trial is to assess the long-term safety and efficacy of GS010, a gene therapy, and assess the quality of life in subjects with LHON due to the G11778A ND4 mitochondrial mutation and who were treated in the Rescue or Reverse studies.
What is the current status of trial NCT03406104?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 62 participants. The study started on 2018-01-09. Estimated completion is 2022-07-04.
What conditions does trial NCT03406104 study?
This clinical trial studies the following conditions: Leber Hereditary Optic Neuropathy.
What interventions are being tested in trial NCT03406104?
The interventions under investigation include: GS010 (GENETIC), Sham Intravitreal Injection (OTHER).
Who is sponsoring clinical trial NCT03406104?
This trial is sponsored by GenSight Biologics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03406104 being conducted?
This trial has 7 study locations across California, Georgia, Pennsylvania, Greater London. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leber Hereditary Optic Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.